Bispecific antibodies specific for OX40

Patent metadata

Field	Value
Publication number	US-10526413-B2
Application number	US-201615280379-A
Country	US
Kind code	B2
Filing date	Sep 29, 2016
Priority date	Oct 2, 2015
Publication date	Jan 7, 2020
Grant date	Jan 7, 2020

Abstract

The invention relates to antibody or antibody fragments thereof that bind to OX40, methods of producing these antibodies and fragments, and to methods of using the same.

First claim

What is claimed is:

1. An antibody or antibody fragment thereof that specifically binds to OX40, wherein said antibody or fragment thereof comprises:
(a) a heavy chain variable domain (VH) comprising
(i) an CDR-H1 comprising the amino acid sequence of SEQ ID NO:2;
(ii) an CDR-H2 comprising the amino acid sequence of SEQ ID NO:4;
(iii) an CDR-H3 comprising the amino acid sequence of SEQ ID NO:7; and

(b) a light chain variable domain (VL) comprising
(i) an CDR-L1 comprising the amino acid sequence of SEQ ID NO:13;
(ii) an CDR-L2 comprising the amino acid sequence of SEQ ID NO:16; and
(iii) an CDR-L3 comprising the amino acid sequence of SEQ ID NO:20.

2. The antibody or fragment thereof of claim 1 , wherein the VH has at least 95% amino acid sequence identity to SEQ ID NO:27, and the VL has at least 95% amino acid sequence identity to SEQ ID NO:28.

3. The antibody or fragment thereof of claim 1 , wherein the VH has at least 97% amino acid sequence identity to SEQ ID NO:27, and the VL has at least 97% amino acid sequence identity to SEQ ID NO:28.

4. The antibody or fragment thereof of claim 1 , wherein the VH has at least 99% amino acid sequence identity to SEQ ID NO:27, and the VL has at least 99% amino acid sequence identity to SEQ ID NO:28.

5. The antibody or fragment thereof of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO:27, and the VL comprises the amino acid sequence of SEQ ID NO:28.

6. The antibody or fragment thereof of claim 1 that is a monoclonal antibody.

7. The antibody or fragment thereof of claim 5 that is a monoclonal antibody.

8. The antibody or fragment thereof of claim 6 that is a humanized or human antibody.

9. The antibody or fragment thereof of claim 7 that is a humanized or human antibody.

10. The antibody or fragment thereof of claim 1 that is a scFv, a Fab, or a Fab' fragment.

11. The antibody or fragment thereof of claim 5 that is a scFv, a Fab, or a Fab' fragment.

12. The antibody or fragment thereof of claim 1 that is an antibody comprising an Fc domain of the human IgG1 subclass.

13. The antibody of claim 12 that comprises the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).

14. The antibody or fragment thereof of claim 5 that is an antibody comprising an Fc domain of the human IgG1 subclass.

15. The antibody of claim 14 that comprises the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).

16. An antibody that specifically binds to OX40, comprising:
(a) a light chain comprising the amino acid sequence of SEQ ID NO:186; and
(b) a heavy chain comprising the amino acid sequence of SEQ ID NO:187.

17. The antibody of claim 16 that is a monoclonal antibody.

18. A composition comprising the antibody or fragment of claim 1 and a pharmaceutically acceptable excipient.

19. A composition comprising the antibody or fragment of claim 5 and a pharmaceutically acceptable excipient.

20. A composition comprising the antibody or fragment of claim 16 and a pharmaceutically acceptable excipient.

Assignees

• Hoffmann La Roche

Inventors

• Amann Maria
• Bruenker Peter
• Claus Christina
• Ferrara Koller Claudia
• Grau-Richards Sandra
• Hosse Ralf
• Klein Christian
• Levitski Viktor
• Umana Pablo

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• C07K16/3053

  Skin, nerves, brain · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title